Navigation Links
Duke vaccine extends survival for patients with deadly brain cancers
Date:10/4/2010

DURHAM, N.C. -- A new vaccine added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma (GBM), the most deadly form of brain cancer, according to a study from researchers at Duke University Medical Center and The University of Texas MD Anderson Cancer Center.

The vaccine also knocks out a troublesome growth factor that characterizes the most aggressive form of the disease.

"About a third of all glioblastomas are fueled by a very aggressive cancer gene, called EGFRvIII; these tumors are the 'worst of the worst,'" said John Sampson, M.D., Ph.D., the Robert H. and Gloria Wilkins Professor of Neurosurgery at Duke.

"Our study showed that the vaccine eliminated all of the cancer cells carrying this marker in all but one of our study participants," said Darell D. Bigner, M.D., Ph.D., director of the Preston Robert Tisch Brain Tumor Center and the senior author of the study.

The EGFRvIII variant was co-discovered by Bert Vogelstein and Albert Wong at Johns Hopkins University and Bigner, at Duke.

The study, appearing in the Journal of Clinical Oncology, involved 18 patients newly diagnosed with GBM from Duke and MD Anderson and a matched set of 17 patients who served as controls. Patients in both groups received surgery, radiation and the chemotherapy drug temozolomide. Patients in the vaccine group began receiving injections one month after completing radiation and stayed on the vaccine as long as it appeared to be working.

Adding the vaccine to standard therapy extended median survival time from an expected 15 months to 26 months. Patients in the vaccine group also experienced a much longer progression-free survival period, 14.2 months, compared to 6.3 months for those who did not receive the vaccine.

Glioblastoma is the most common form of brain cancer with roughly 10,000 new cases arising in the U.S. each year. The presence of EGFRvIII allows cancer cells to grow wildly out of control, seeding new tumors throughout the brain. Despite some advances in radiation and chemotherapy, the prognosis for patients with such tumors is grim; on average they live just over one year following initial diagnosis.

Sampson says new therapies are critical. Over the past decade he and his research team have been working on several new vaccine strategies. The particular vaccine used in this study is called a peptide vaccine and was designed to stimulate the patient's immune systems to respond to a particular part of a protein on EGFRvIII.

Other brain tumor vaccine studies are in progress at other institutions with peptides drawn from the tumors and with heat shock proteins.

Researchers found that the vaccine (variously known as CDX-110 by Celldex Therapeutics, and Rindopepimut (PF-04948568) by Pfizer) stimulated an immune response in approximately half of the patients who received it. Six patients developed EGFRvIII-specific antibodies and three developed T-cell responses.

The data suggest that these responses are linked to increased survival time, "but the numbers are so small that we can not conclude this with any degree of certainty," says Amy Heimberger, MD, co-lead investigator, from MD Anderson.

Scientists were also able to examine pre- and post-vaccination tumor samples from 11 patients and found that when their tumors recurred, 82 percent lacked immunoreactivity, which Sampson says demonstrates that the vaccine had done its job in eliminating the most aggressive cells.

Sampson notes that the EGFRvIII vaccine may be worth further investigation because this growth factor is also found in other kinds of cancer cells, but not in normal tissue, making it a good target for intervention.

Bigner says that even though the study is small, the findings are intriguing and merit further study. "This appears to be a promising start, but the biological complexity of these tumors suggests that we may need multiple agents to attack additional markers of tumor growth or treatment resistance to be wholly successful."

Duke has a long history of vaccine design and Sampson says plans are already under way to couple the vaccine with another designed to strengthen T-cell responses.


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-724-5343
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Vaccine May Prevent TB in People With HIV
2. Vaccine Not Fail-Safe in Ongoing Mumps Outbreak
3. New strategy produces promising advance in cancer vaccines
4. Screens, Vaccine for HPV Less Beneficial in Older Women
5. New Technology Could Widen Reach of Vaccines
6. Texas-based consortium announces groundbreaking vaccine research program
7. The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies Failure to Provide Adequate Safety Research
8. Possible vaccine for mesothelioma proven safe
9. Groundbreaking research to find vaccine for hepatitis C
10. Vaccine for Asbestos-Related Cancer Looks Safe
11. CDC Awards Abt Associates Additional Contracts to Evaluate Effectiveness of H1N1 Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Phycologia ... A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested the magnitude ... pair observed that when photosynthetically active radiation (i.e. the white light in our ...
(Date:5/5/2016)... ... May 05, 2016 , ... Every ... the most heartfelt wishes of these children. The wishes provide hope and ... President and CEO of Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the organization ...
(Date:5/5/2016)... ... , ... Long Island’s fastest growing comprehensive eye care provider, North Shore ... Van Valkenburg, MD as part of their ongoing effort to increase ophthalmic coverage in ... partner of North Shore Eye Care. , “We are extremely proud to welcome ...
(Date:5/5/2016)... ... , ... TIME for Kids and The ZAC Foundation – a national leader ... nearly 1 million children with important water safety messages before summer break begins. ... accidental death in children one to 6 years of age. TIME for Kids ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses Week ... all over the United States to thank a nurse who's made a difference in ... $5 to the American Red Cross of San Diego/Imperial Counties (up to $10,000) every ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... , May 3, 2016 ACME ... Whelan and Delaware County Councilman ... Nasal Spray in all ACME pharmacies across ... for Disease Control and Prevention (CDC), naloxone has saved 26,463 lives ... officers in Delaware County were authorized to ...
Breaking Medicine Technology: